Next Article in Journal
Cellular and Extracellular Proteome of the Animal Pathogen Corynebacterium silvaticum, a Close Relative of Zoonotic Corynebacterium ulcerans and Corynebacterium pseudotuberculosis
Next Article in Special Issue
Serum Glycoproteomic Alterations in Patients with Diabetic Retinopathy
Previous Article in Journal
What Room for Two-Dimensional Gel-Based Proteomics in a Shotgun Proteomics World?
Previous Article in Special Issue
Is It Possible to Find Needles in a Haystack? Meta-Analysis of 1000+ MS/MS Files Provided by the Russian Proteomic Consortium for Mining Missing Proteins
Open AccessReview

New Insights into Inflammatory Bowel Diseases from Proteomic and Lipidomic Studies

Department of Biological and Environmental Sciences and Technologies, University of Salento, via Monteroni 165, 73100 Lecce, Italy
National Institute of Gastroenterology “S. de Bellis”, Institute of Research, Via Turi, 27, 70013 Castellana Grotte, Italy
Department of Mathematics and Physics “Ennio De Giorgi”, University of Salento, via Monteroni, 73100 Lecce, Italy
Authors to whom correspondence should be addressed.
Proteomes 2020, 8(3), 18;
Received: 29 April 2020 / Revised: 4 August 2020 / Accepted: 7 August 2020 / Published: 10 August 2020
(This article belongs to the Special Issue Human Proteomics)
Ulcerative colitis (UC) and Crohn’s disease (CD) represent the two main forms of chronic inflammatory bowel diseases (IBD). The exact IBD etiology is not yet revealed but CD and UC are likely induced by an excessive immune response against normal constituents of the intestinal microbial flora. IBD diagnosis is based on clinical symptoms often combined with invasive and costly procedures. Thus, the need for more non-invasive markers is urgent. Several routine laboratory investigations have been explored as indicators of intestinal inflammation in IBD, including blood testing for C-reactive protein, erythrocyte sedimentation rate, and specific antibodies, in addition to stool testing for calprotectin and lactoferrin. However, none has been universally adopted, some have been well-characterized, and others hold great promise. In recent years, the technological developments within the field of mass spectrometry (MS) and bioinformatics have greatly enhanced the ability to retrieve, characterize, and analyze large amounts of data. High-throughput research allowed enhancing the understanding of the biology of IBD permitting a more accurate biomarker discovery than ever before. In this review, we summarize currently used IBD serological and stool biomarkers and how proteomics and lipidomics are contributing to the identification of IBD biomarkers. View Full-Text
Keywords: Crohn’s disease; lipidomics; markers; proteomics; ulcerative colitis Crohn’s disease; lipidomics; markers; proteomics; ulcerative colitis
Show Figures

Graphical abstract

MDPI and ACS Style

Longo, S.; Chieppa, M.; Cossa, L.G.; Spinelli, C.C.; Greco, M.; Maffia, M.; Giudetti, A.M. New Insights into Inflammatory Bowel Diseases from Proteomic and Lipidomic Studies. Proteomes 2020, 8, 18.

AMA Style

Longo S, Chieppa M, Cossa LG, Spinelli CC, Greco M, Maffia M, Giudetti AM. New Insights into Inflammatory Bowel Diseases from Proteomic and Lipidomic Studies. Proteomes. 2020; 8(3):18.

Chicago/Turabian Style

Longo, Serena; Chieppa, Marcello; Cossa, Luca G.; Spinelli, Chiara C.; Greco, Marco; Maffia, Michele; Giudetti, Anna M. 2020. "New Insights into Inflammatory Bowel Diseases from Proteomic and Lipidomic Studies" Proteomes 8, no. 3: 18.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop